TheraRadar
← Back
Data updated: Jun 28, 2026

QUESTCOR PHARMA

Pharma

QUESTCOR PHARMA is a pharmaceutical company focused on Immunology, Neurology.

2010
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

QUESTCOR PHARMA's Key Drugs

QUESTCOR PHARMA's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

QUESTCOR PHARMA's Recent FDA Approvals

New NDA/BLA approvals for QUESTCOR PHARMA over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

QUESTCOR PHARMA's Therapeutic Areas

QUESTCOR PHARMA's approved drugs and pipeline span 2 therapeutic areas, led by Immunology and Neurology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Immunology 50%
1 drugs
Neurology 50%
1 drugs

QUESTCOR PHARMA's Top Competitors

QUESTCOR PHARMA's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

QUESTCOR PHARMA Pipeline Snapshot

Active clinical trials for QUESTCOR PHARMA across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Immunology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling